Aims and scope
A major focus of the journal is on the immunologic processes leading to inflammation, damage and repair as they relate to autoimmune rheumatic and musculoskeletal conditions, and which inform the translation of this knowledge into advances in clinical care.
Original basic, translational and clinical research is considered for publication along with results of early and late phase therapeutic trials, especially as they pertain to the underpinning science that informs clinical observations in interventional studies.
Review series: New technologies
Written by renowned experts in the field, this collection of open access Review articles explores the use of RNA sequencing, cytometry, metabolomics and next-generation DNA sequencing in rheumatic disease.
Reflections of a rheumatologist
Featured review: Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis
In this review, Bustamante and colleagues show how fibroblast-like synoviocytes in RA patients differ from healthy synovial fibroblasts, not only in their marker expression, proto-oncogene expression, or their epigenetic changes, but also in their intracellular metabolism.
"Whether this truly constitutes an option to increase the drug armamentarium in rheumatic diseases beyond biological and kinase inhibitor therapies remains to be determined."
2017 Journal Metrics
62 days to first decision for reviewed manuscripts only
50 days to first decision for all manuscripts
136 days from submission to acceptance
27 days from acceptance to publication